Abstract: The present invention provides a pharmaceutical composition for treating a tumor, the pharmaceutical composition comprising (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydr o-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide represented by formula (I) or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition is administered in combination with an RAS inhibitor.

Abstract: Light emitting devices and display devices with improved aperture ratio and suppressed current leakage between electrodes are disclosed. In one example, a light emitting device includes a substrate, a laminated structure, and an electrode relay portion. The laminated structure includes first through third electrodes and first and second organic layers. The second electrode is a common electrode corresponding to the first and third electrodes. A wall surface portion includes a connecting surface in which a sidewall of the first organic layer, a sidewall of the second electrode, and a sidewall of the second organic layer are connected. A sidewall insulating layer covers at least a part of the wall surface portion, and the electrode relay portion extends from the third electrode toward the substrate, and passes over an outer surface of the wall surface portion via the sidewall insulating layer.

Abstract: The present invention has been made in view of the foregoing, and an object thereof is to provide a method for learning a threshold that can provide a more objective threshold applied to pixels in the mammography image. The present invention provides a method for learning a threshold value applied to pixels in a mammography image comprising: an acquiring step; and a learning step, wherein in the acquiring step, the mammography image is acquired, in the learning step, a relationship between the mammography image and a mammary gland pixel estimation threshold is learned, the mammary gland pixel estimation threshold is a threshold value used to calculate a mammary gland pixel area of each pixel of a mammary gland region in the mammography image, and the mammary gland pixel area is a value indicating a degree of a mammary gland pixel-likeness of the pixel in the mammography image.

Abstract: Non-liposome, non-micelle particles formed of a lipid, an additional adjuvant such as a TLR4 agonist, a sterol, and a saponin are provided. The particles are porous, cage-like nanoparticles, also referred to as nanocages, and are typically between about 30 nm and about 60 nm. In some embodiments, the nanocages include or are administered in combination with an antigen. The particles can increase immune responses and are particularly useful as adjuvants in vaccine applications and related methods of treatment. Preferred lipids, additional adjuvants including TLR4 agonists, sterols, and saponins, methods of making the nanocages, and method of using them are also provided.

Abstract: An organic EL (Light-Emitting) device is provided that includes at least two subpixels, including a first subpixel and a second subpixel. The first subpixel includes a first electrode, a first organic compound layer with first side surfaces, a first light-emitting layer that emits light of a first color, a second electrode, and a first film covering the first side surfaces with a specified thickness. The second subpixel includes a third electrode, a second organic compound layer with second side surfaces, a second light-emitting layer that emits light of a second color different from the first, a fourth electrode, and a second film covering the second side surfaces with a different thickness from the first film. The first electrode, the first organic compound layer, and the second electrode are stacked in a direction. The first subpixel is spaced apart from the second subpixel on a plane perpendicular to the direction.

Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor, and the use of the combination therapies for the treatment of cancer. The multi-RTK inhibitor may be represented by Formula (I): wherein R1 is C1-6 alkyl or C3-8 cycloalkyl, R2 is a hydrogen atom or C1-6 alkoxy, and R3 is a hydrogen atom or a halogen atom. A tumor therapeutic agent is disclosed that combines a compound or pharmaceutically acceptable salt thereof represented by Formula I and an anti-PD-1 antibody.

Abstract: A recovery device for a volatile organic compound is a device for recovering the volatile organic compound in a coating drying oven which dries a coating film of a workpiece coated with a water-soluble coating. The coating drying oven includes: an evaporation zone in which moisture of the workpiece is evaporated; and a curing zone to cure the coating film. The recovery device includes: a first take-out passage for taking out first furnace air in the evaporation zone; a second take-out passage for taking out second furnace air in the curing zone; a mixing chamber configured to mix the first furnace air and the second furnace air to obtain mixed air; and a cooling recovery unit configured to cool the mixed air and recover, as a condensate, the volatile organic compound contained in the mixed air, together with the moisture.

Abstract: An organic EL device is constructed with a structure that can prevent deterioration in characteristics. An organic EL device is provided that includes at least two or more subpixels each including an organic compound layer including at least a light-emitting layer that emits light of a different color from the other light-emitting layer(s), the organic compound layer being interposed between a first electrode and a second electrode in a stacking manner, the subpixels being disposed separately from one another on a plane perpendicular to a direction of the stacking. Lateral surfaces of the organic compound layers are covered with films differing from subpixel to subpixel. This structure can prevent the organic EL device from deterioration in characteristics.

Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a multi-RTK inhibitor, and the use of the combination therapies for the treatment of cancer. The multi-RTK inhibitor may be represented by Formula (I): wherein R1 is C1-6 alkyl or C3-8 cycloalkyl, R2 is a hydrogen atom or C1-6 alkoxy, and R3 is a hydrogen atom or a halogen atom. A tumor therapeutic agent is disclosed that combines a compound or pharmaceutically acceptable salt thereof represented by Formula I and an anti-PD-1 antibody.

Abstract: Biomarkers are provided that predict whether a human subject having a tumor is in need of a therapy comprising an angiogenesis inhibitor (e.g. lenvatinib or a pharmaceutically acceptable salt thereof, such as lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having a tumor.

Abstract: A hydraulic reservoir of a human-powered vehicle comprises a reservoir structure and a bleeding plug. The reservoir structure includes a reservoir chamber, a bleeding port, and a connecting port. The bleeding port is configured to be in communication with the reservoir chamber. The bleeding port has a bleeding-port inner diameter. The connecting port is configured to connect the reservoir chamber and a hydraulic chamber. The hydraulic chamber is at least partially defined by a piston. The reservoir structure includes an intermediate port through which a fluid is to flow from the connecting port to the bleeding port when bleeding the hydraulic reservoir. The intermediate port has an intermediate-port inner diameter smaller than the bleeding-port inner diameter. The bleeding plug is configured to be attached to the bleeding port.

Abstract: An operating device for a human-powered vehicle comprises a base, a piston, an operating member, an intermediate member, and a mounting structure. The base includes a hole. The piston is movably provided in the hole. The operating member is pivotally coupled to the base about a first pivot axis. The intermediate member is pivotally coupled to the base about a second pivot axis to transmit a pivotal movement of the operating member to the piston. The mounting structure is configured to couple the base and a handlebar of the human-powered vehicle. The mounting structure defines a mounting axis extending along the handlebar in a mounting state where the mounting structure couples the base and the handlebar. The first pivot axis is closer to the mounting axis than the second pivot axis in a perpendicular direction perpendicular to the mounting axis as viewed along the first pivot axis.

Abstract: A display apparatus includes display elements formed on a substrate and arrayed in a two-dimensional matrix, the display elements each having a light emitting unit formed by stacking a lower electrode, an organic layer, and an upper electrode, wherein the lower electrode and the organic layer are provided for each light emitting unit, the substrate includes a groove formed in a part of the substrate positioned between adjacent light emitting units, the groove having a bottom surface and both side surfaces forming a gentle inclination angle with respect to the bottom surface, and a protective film is formed in common on entire surface including an upper surface of the light emitting unit and an upper surface of the groove of the substrate.

Abstract: The present invention has been made in view of the foregoing, and an object thereof is to provide an information processing device capable of appropriately determining a necessity of the ultrasonography even when a high-density mammary gland area exists in a narrow area. The present invention provides an information processing device comprising: a mammary gland area extractor configured to extract a mammary gland area in a mammography image; a mammary gland pixel detector configured to detect a mammary gland pixel in the mammary gland area; and a mammary gland density calculator configured to calculate a mammary gland density based on a ratio of the mammary gland pixels to the mammary gland area, wherein the mammary gland area is a narrower area than an entire breast in the mammography image.

Abstract: There is provided an imaging device including an upper electrode; a lower electrode; a photoelectric conversion layer disposed between the upper electrode and the lower electrode; and a first organic semiconductor material including an indolocarbazole derivative and disposed between the upper electrode and the lower electrode. Further, there is provided an electronic apparatus including an imaging device that includes an upper electrode; a lower electrode; a photoelectric conversion layer disposed between the upper electrode and the lower electrode; and a first organic semiconductor material including an indolocarbazole derivative and disposed between the upper electrode and the lower electrode.

Abstract: Provided is a pharmaceutical composition for treating a tumor, comprising 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxyl-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or its pharmaceutically acceptable salt, which is to be administered in combination with a PD-1 antagonist.

Abstract: An organic EL device is constructed with a structure that can prevent deterioration in characteristics. An organic EL device is provided that includes at least two or more subpixels each including an organic compound layer including at least a light-emitting layer that emits light of a different color from the other light-emitting layer(s), the organic compound layer being interposed between a first electrode and a second electrode in a stacking manner, the subpixels being disposed separately from one another on a plane perpendicular to a direction of the stacking. Lateral surfaces of the organic compound layers are covered with films differing from subpixel to subpixel. This structure can prevent the organic EL device from deterioration in characteristics.

Abstract: An operating device for a human-powered vehicle comprises a base, a piston, an operating member, an intermediate member, and a mounting structure. The base includes a hole. The piston is movably provided in the hole. The operating member is pivotally coupled to the base about a first pivot axis. The intermediate member is pivotally coupled to the base about a second pivot axis to transmit a pivotal movement of the operating member to the piston. The mounting structure is configured to couple the base and a handlebar of the human-powered vehicle. The mounting structure defines a mounting axis extending along the handlebar in a mounting state where the mounting structure couples the base and the handlebar. The first pivot axis is closer to the mounting axis than the second pivot axis in a perpendicular direction perpendicular to the mounting axis as viewed along the first pivot axis.

Abstract: An organic EL device is constructed with a structure that can prevent deterioration in characteristics. An organic EL device is provided that includes at least two or more subpixels each including an organic compound layer including at least a light-emitting layer that emits light of a different color from the other light-emitting layer(s), the organic compound layer being interposed between a first electrode and a second electrode in a stacking manner, the subpixels being disposed separately from one another on a plane perpendicular to a direction of the stacking. Lateral surfaces of the organic compound layers are covered with films differing from subpixel to subpixel. This structure can prevent the organic EL device from deterioration in characteristics.

Abstract: Non-liposome, non-micelle particles formed of a lipid, an additional adjuvant such as a TLR4 agonist, a sterol, and a saponin are provided. The particles are porous, cage-like nanoparticles, also referred to as nanocages, and are typically between about 30 nm and about 60 nm. In some embodiments, the nanocages include or are administered in combination with an antigen. The particles can increase immune responses and are particularly useful as adjuvants in vaccine applications and related methods of treatment. Preferred lipids, additional adjuvants including TLR4 agonists, sterols, and saponins, methods of making the nanocages, and method of using them are also provided.